BiotechTube
AUM BioTech

AUM BioTech

Philadelphia, United States· Est.
aumbiotech.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Founded in 2015, AUM BioTech has developed a proprietary platform of self-delivering antisense oligonucleotides (sdASOs) designed for transfection-free gene silencing. Its technology aims to overcome key challenges in RNA therapeutics, particularly the efficient delivery into difficult-to-transfect primary cells like immune cells and neurons. The company currently operates as a research tools and services provider, offering a portfolio of silencing products to academic and industrial researchers for target validation and functional genomics. Its long-term vision likely involves therapeutic development, leveraging the delivery advantages of its sdASO platform.

RNA TherapeuticsGenetics & Genomics

Technology Platform

Self-delivering antisense oligonucleotide (sdASO) platform utilizing next-gen chemical modifications and AI-driven design for transfection-free gene silencing in vitro and in vivo.

Opportunities

The platform addresses the major delivery challenge in RNA therapeutics, enabling efficient silencing in hard-to-transfect primary cells critical for immunology and neurology research.
Successful research tool adoption creates a direct path to therapeutic development in high-value areas like genetic disorders, oncology, and antiviral applications.

Risk Factors

Key risks include the need for broad, independent validation of its high-efficiency claims, competition in the crowded research tools market, and the significant technical and financial hurdles in translating a research platform into approved human therapeutics.

Competitive Landscape

In research tools, AUM competes with established reagent companies (Thermo Fisher, Horizon Discovery) and specialized RNAi providers. In therapeutics, it would face competition from large oligonucleotide players (Ionis, Alnylam) and biotechs using LNP or viral delivery. Its differentiation is the combination of high efficiency and transfection-free delivery.

More companies in RNA Therapeutics (non-mRNA) →More companies in United States →